Hims & Hers shares tumble 18% as margin miss adds to concerns about GLP-1 business
Hims & Hers Health reported fourth-quarter results on Monday that beat analysts’ expectations, but the stock sank in extended ...
Hims & Hers: Capitalizing On The GLP-1 Rush Before The Window Closes (Rating Upgrade)
Hims & Hers projects $725M in GLP-1 weight loss revenue for 2025, a 3.2x increase from 2024. Read why I upgrade HIMS stock ...
ABC 10 News2h
Hims and Hers likely to stop selling cheaper versions of GLP-1 medications
The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...
Hims & Hers (HIMS) Sees 69% Revenue Increase Despite GLP-1 Uncertainties
Hims & Hers Health (HIMS) has seen its shares decline over 17% in the past week since the U.S. Food and Drug Administration (FDA) announced ...
Fierce Healthcare3d
FDA declares semaglutide shortage over, spelling end to compounded GLP-1 market, for now
The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and ...
FDA gives compounders short reprieve as Novo Nordisk GLP-1 supply normalizes
Novo Nordisk's (NVO) weight loss therapy Wegovy/Ozempic come out of shortage, but the FDA won't crack down on compounders ...
Hosted on MSN4d
Hims & Hers (HIMS) Down 21% – Is the GLP-1 Gravy Train Over?
Shares of Hims & Hers Health (NYSE:HIMS) are down about 21%, or $14. All on news the Ozempic shortage is over. Key Points ...
pharmaphorum2d
Pharma group slams Hims & Hers over Super Bowl GLP-1 ad
An ad for compounded versions of weight-loss drug semaglutide by telehealth company Hims & Hers has attracted ... of a prescription medicine. GLP-1 agonist semaglutide is the active ingredient ...
Hims & Hers shares plunge 28% on concerns over weight loss business, margins
Hims & Hers on Monday released fourth-quarter results that disappointed on gross margin and sparked concerns about the future ...